VENTRIPOINT DIAGNOSTICS LTD ("VPT-V;VPTDF-0")
Results of Annual Shareholders' Meeting and Grant Of Stock
Options and Deferred Share Units
Seattle, Washington, September 23, 2014 - Ventripoint Diagnostics Ltd. announces that at its Annual General Meeting on September 18, 2014 the shareholders elected Dr. George Adams, Mr. Danny Dalla-Longa, Mr. Bradley Harlow and Mr. Treuman Katz as Directors of the Corporation. They further approved the Incentive Stock Option plan, amendments to the Deferred Share Unit plan (DSU plan), amendments to the By-Laws of the Corporation, and gave authority to the Board of Directors to undertake a share consolidation if it deems the consolidation in the best interests of the Corporation. BDO was appointed as auditors of the Corporation for the next year.
The Board of Directors has granted 2,500,000 stock options to certain officers of the Corporation. The options are exercisable at $0.08 per share until the fifth anniversary date of the grant. In addition, the Corporation announces that it has granted a total of 900,000 Deferred Share Units (DSUs) to certain directors. Under the terms of the Corporation's DSU plan, holders of DSUs may redeem each DSU for one share of Common Stock upon the termination of their services to the Corporation, at no cost to the holder.
About Ventripoint Diagnostics Ltd.
Ventripoint has created tools to monitor patients with heart disease, a leading cause of death in developed countries. VMS™ is the first cost-effective and accurate tool for measuring right ventricle heart function. The Corporation has a suite of applications for all major heart diseases and imaging modalities including congenital heart disease, left or right heart failure and normal hearts - a multi-billion dollar market potential.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
FORWARD-LOOKING STATEMENTS: The statements made in this news release that are not historical facts may contain forward-looking information that involves risk and uncertainties. All statements, other than statements of historical facts, which address Ventripoint’s expectations, should be considered forward-looking statements. Such statements are based on management’s exercise of business judgment as well as assumptions made by and information currently available to management. When used in this document, the words "may", "will", "anticipate", "believe", "estimate", "expect", "intend" and words of similar import, are intended to identify any forward-looking statements. You should not place undue reliance on these forward-looking statements. These statements reflect a current view of future events and are subject to certain risks and uncertainties as contained in the Corporation's filings with Canadian securities regulatory authorities. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results could differ materially
from those anticipated in these forward-looking statements. A description of assumptions used to develop such forward-looking information and a description of risk factors that may cause actual results to differ materially from forward-looking information can be found in Ventripoint's disclosure documents on the SEDAR website at www.sedar.com. The Corporation undertakes no obligation, and does not intend, to update, revise or otherwise publicly release any revisions to these forward-looking
statements to reflect events or circumstances after the date hereof, or to reflect the occurrence of any unanticipated events. Although management believes that expectations are based on reasonable assumptions, no assurance can be given that these expectations will materialize.